JIDEYTRO

This brand name is authorized in United States.

Active ingredients

The drug JIDEYTRO contains one active pharmaceutical ingredient (API):

1
UNII MX5KQV5XHC - ZIDESAMTINIB
 

Zidesamtinib is an inhibitor of tyrosine kinase ROS1, including ROS1 resistance mutations In vitro, zidesamtinib inhibited the viability of cultured cells expressing ROS1 fusion genes and resistance mutations (G2032R, S1986F, F2004C/V, L2026M, D2033N, and G2101A). In mice subcutaneously implanted with tumors harboring ROS1 fusions, including the G2032R mutation, administration of zidesamtinib resulted in tumor growth inhibition. Zidesamtinib had antitumor activity in an intracranial NSCLC xenograft model harboring a ROS1 fusion.
 
Read more about Zidesamtinib

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 JIDEYTRO Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
US FDA, National Drug Code 85001-101, 85001-102

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈